Cite
HARVARD Citation
Ghobrial, I. et al. (n.d.). Long‐term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. American journal of hematology. 89 (3), pp. 237-242. [Online].